COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
Annika FendlerElisabeth G E de VriesCorine H GeurtsvanKesselJohn B A G HaanenBernhard WörmannSamra TurajlicMarie von Lilienfeld-ToalPublished in: Nature reviews. Clinical oncology (2022)
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- immune response
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- respiratory syndrome coronavirus
- healthcare
- prognostic factors
- peritoneal dialysis
- dendritic cells
- type diabetes
- risk assessment
- coronary artery disease
- toll like receptor
- human health
- open label
- current status
- drug induced